Finch Stock Analysis

FNCH -  USA Stock  

USD 2.28  0.21  10.14%

The big decline in price over the last few months for Finch Therapeutics could raise concerns from stockholders as the firm is trading at a share price of 2.28 on 489,400 in volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in April. However, diversifying your holdings with Finch Therapeutics Group or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.19. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Finch Therapeutics partners.
Please check Investing Opportunities.
  
Refresh
The Finch Therapeutics stock analysis report makes it easy to digest most publicly released information about Finch Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Finch Stock analysis module also helps to analyze the Finch Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Finch Stock Analysis Notes

About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.48. Some equities with similar Price to Book (P/B) outperform the market in the long run. Finch Therapeutics recorded a loss per share of 1.78. The entity had not issued any dividends in recent years. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people. To learn more about Finch Therapeutics Group call the company at 617 229 6499 or check out https://www.finchtherapeutics.com.

Finch Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Finch Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Finch Therapeutics Group or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Finch Therapeutics generated a negative expected return over the last 90 days
Finch Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 18.53 M. Net Loss for the year was (58.16 M) with loss before overhead, payroll, taxes, and interest of (38.75 M).
Finch Therapeutics Group currently holds about 133.48 M in cash with (67.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 51.0% of the company shares are held by company insiders
Latest headline from www.benzinga.com: Finch Therapeutics Announces Removal Of FDA Clinical Hold On CP101 IND - Benzinga - Benzinga

Finch Therapeutics Upcoming and Recent Events

Earnings reports are used by Finch Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Finch Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of February 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End9th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Finch Largest EPS Surprises

Earnings surprises can significantly impact Finch Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-10
2021-06-30-0.28-0.32-0.0414 
2022-03-31
2021-12-31-0.32-0.4-0.0825 
2021-11-10
2021-09-30-0.42-0.210.2150 
View All Earnings Estimates

Finch Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Finch Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Finch Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Finch Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
16th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
28th of April 2022
Financial Statements and Exhibits. Other Events
View
19th of April 2022
Financial Statements and Exhibits. Other Events. Cost Associated with Exit or Disposal Activities
View
31st of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
1st of March 2022
Financial Statements and Exhibits. Other Events
View
14th of February 2022
Unclassified Corporate Event
View
10th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
10th of November 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View

Finch Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Finch Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Finch Therapeutics Group backward and forwards among themselves. Finch Therapeutics' institutional investor refers to the entity that pools money to purchase Finch Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Susquehanna International Group LlpCommon Shares1.8 M8.9 M
Avenir Management Company LlcCommon Shares1.7 M8.4 M
Baupost Group LlcCommon Shares1.1 M5.6 M
Bleichroeder LpCommon Shares810.4 K4.1 M
Vanguard Group IncCommon Shares794.3 KM
Lake Street Advisors Group LlcCommon Shares739.1 K3.7 M
Light Street Capital Management LlcCommon Shares668.8 K3.4 M
Note, although Finch Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Finch Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 105.4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Finch Therapeutics's market, we take the total number of its shares issued and multiply it by Finch Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Finch Profitablity

Finch Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Finch Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Finch Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Finch Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Finch Therapeutics' profitability requires more research than a typical breakdown of Finch Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.24) (0.26) 
Return on Average Equity(0.26) (0.27) 
Return on Invested Capital(1.05) (1.13) 
Return on Sales(3.14) (3.38) 

Management Efficiency

The entity has return on total asset (ROA) of (19.19) % which means that it has lost $19.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (34.26) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics management efficiency ratios could be used to measure how well finch therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Assets is estimated to decrease to -0.26. The current Return on Average Equity is estimated to decrease to -0.27. Finch Therapeutics Asset Turnover is most likely to increase slightly in the upcoming years. The last year's value of Asset Turnover was reported at 0.08. The current Tangible Assets Book Value per Share is estimated to increase to 7.71, while Total Assets are projected to decrease to roughly 214 M.
Last ReportedProjected for 2022
Book Value per Share 5.16  5.57 
Enterprise Value over EBIT(5.40) (5.83) 
Enterprise Value over EBITDA(5.22) (5.63) 
Price to Book Value 2.11  2.09 
Tangible Assets Book Value per Share 5.29  7.71 
Enterprise Value291.7 M290 M
Tangible Asset Value207.3 M194 M

Technical Drivers

As of the 23rd of May, Finch Therapeutics shows the coefficient of variation of (325.90), and Mean Deviation of 4.45. Finch Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Finch Therapeutics Group, which can be compared to its rivals. Please confirm Finch Therapeutics maximum drawdown, and the relationship between the information ratio and downside variance to decide if Finch Therapeutics is priced favorably, providing market reflects its regular price of 2.28 per share. Please also check Finch Therapeutics Group total risk alpha, which is currently at (1.12) to verify the company can sustain itself at a future point.

Finch Therapeutics Price Movement Analysis

Study
Time Period
Deviations up
Deviations down
MA Type
Execute Study
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Finch Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Finch Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Finch Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Finch Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Finch Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Finch Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Finch Therapeutics Predictive Daily Indicators

Finch Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Finch Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Finch Therapeutics Forecast Models

Finch Therapeutics time-series forecasting models is one of many Finch Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Finch Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Finch Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Finch Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Finch shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Finch Therapeutics. By using and applying Finch Stock analysis, traders can create a robust methodology for identifying Finch entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(3.01) (3.25) 
Gross Margin 1.15  1.18 
Profit Margin(3.14) (3.38) 
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.

Current Finch Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Finch analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Finch analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
30.0Strong Buy3Odds
Finch Therapeutics Group current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Finch analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Finch stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Finch Therapeutics, talking to its executives and customers, or listening to Finch conference calls.
Finch Analyst Advice Details

Finch Stock Analysis Indicators

Finch Therapeutics Group stock analysis indicators help investors evaluate how Finch Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Finch Therapeutics shares will generate the highest return on investment. By understating and applying Finch Therapeutics stock analysis, traders can identify Finch Therapeutics position entry and exit signals to maximize returns.
Quick Ratio9.06
Fifty Two Week Low1.7120
Revenue Growth-55.40%
Shares Short Prior Month214.48k
Average Daily Volume Last 10 Day325.22k
Average Daily Volume In Three Month985.7k
Shares Percent Shares Out0.40%
Gross Margins-209.08%
Short Percent Of Float0.72%
Forward Price Earnings-0.97
Float Shares22.4M
Fifty Two Week High22.1000
Enterprise Value To Ebitda0.12
Fifty Day Average3.9942
Two Hundred Day Average9.9166
Enterprise Value To Revenue-0.39
Please check Investing Opportunities. Note that the Finch Therapeutics information on this page should be used as a complementary analysis to other Finch Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Finch Stock analysis

When running Finch Therapeutics price analysis, check to measure Finch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Finch Therapeutics is operating at the current time. Most of Finch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Finch Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Finch Therapeutics' price. Additionally, you may evaluate how the addition of Finch Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Finch Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Finch Therapeutics. If investors know Finch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Finch Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Finch Therapeutics is measured differently than its book value, which is the value of Finch that is recorded on the company's balance sheet. Investors also form their own opinion of Finch Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Finch Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Finch Therapeutics' market value can be influenced by many factors that don't directly affect Finch Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Finch Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.